Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.

[1]  P. Tassone,et al.  The Era of PARP inhibitors in ovarian cancer: "Class Action" or not? A systematic review and meta-analysis. , 2018, Critical reviews in oncology/hematology.

[2]  A. Toss,et al.  PARP Inhibitors for the Treatment of Ovarian Cancer. , 2018, Current cancer drug targets.

[3]  A. Oza,et al.  Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  A. Oza,et al.  Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Karl Kashofer,et al.  Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. , 2018, Pathology, research and practice.

[6]  F. Mignone,et al.  A comprehensive BRCA1/2 NGS pipeline for an immediate Copy Number Variation (CNV) detection in breast and ovarian cancer molecular diagnosis. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[7]  G. Scambia,et al.  A Whole Germline BRCA2 Gene Deletion: How to Learn from CNV In Silico Analysis , 2018, International journal of molecular sciences.

[8]  Miika Ahdesmäki,et al.  An evaluation of the challenges to developing tumor BRCA1 and BRCA2 testing methodologies for clinical practice , 2017, Human mutation.

[9]  V. Gebski,et al.  Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[10]  P. Schirmacher,et al.  Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients. , 2017, Seminars in oncology.

[11]  Juanita Lopez,et al.  Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. , 2017, European journal of cancer.

[12]  B. Arun,et al.  BRCA mutation genetic testing implications in the United States. , 2017, Breast.

[13]  B. Monk,et al.  Trabectedin as a chemotherapy option for patients with BRCA deficiency. , 2016, Cancer treatment reviews.

[14]  Ignace Vergote,et al.  Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. , 2016, The New England journal of medicine.

[15]  A. Marchetti,et al.  Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients. , 2016, Future oncology.

[16]  A. Bryant,et al.  Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. , 2015, The Cochrane database of systematic reviews.

[17]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[18]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial , 2014 .

[19]  J. Jonkers,et al.  Opportunities and hurdles in the treatment of BRCA1-related breast cancer , 2014, Oncogene.

[20]  D. Matei,et al.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[21]  Borut Peterlin,et al.  Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic) , 2013, European Journal of Human Genetics.

[22]  J. George,et al.  Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with BRCA1 and BRCA2 Mutations , 2013, Clinical Cancer Research.

[23]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[24]  J. George,et al.  BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Douglas F. Easton,et al.  Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. , 2012, JAMA.

[26]  A. Gabizon,et al.  BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin , 2011, Molecular Cancer Therapeutics.

[27]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[28]  A. Spurdle,et al.  Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.

[29]  I. Jacobs,et al.  BRCA1 and BRCA2 Mutation Prevalence and Clinical Characteristics of a Population-Based Series of Ovarian Cancer Cases from Denmark , 2008, Clinical Cancer Research.

[30]  R. Buller,et al.  Inactivation of BRCA1 and BRCA2 in ovarian cancer. , 2002, Journal of the National Cancer Institute.

[31]  A. Devereau,et al.  Practice Guidelines for the Evaluation of Pathogenicity and the Reporting of Sequence Variants in Clinical Molecular Genetics . , 2013 .